ArticlePharmaceuticals (Basel, Switzerland)2022

Preclinical Studies of Chiauranib Show It Inhibits Transformed Follicular Lymphoma through the VEGFR2/ERK/STAT3 Signaling Pathway.

Yuanfang Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.